A Single Arm, Multi-Center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-Based Chemotherapy.

Trial Profile

A Single Arm, Multi-Center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-Based Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms RAD001
  • Most Recent Events

    • 26 Sep 2012 New source identified and integrated (DRKS00004017: German Clinical Trials Register).
    • 02 Aug 2012 Planned end date changed from 1 Dec 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Actual patient number (28) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top